Objectives: Multiple clinical trials have been conducted to investigate the therapeutic effects of blinatumomab on acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL).
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse. In general, pediatric treatment regimens are more intense than those employed in adults and include courses of combination chemotherapy.
Amgen announced submission of a Biologics License Application (BLA) to the FDA seeking approval for its investigational bispecific T cell...
Areas covered: This article provides an overview of the evolution of immunotherapy for NMIBC, beginning from the original immunotherapy-BCG - to current agents including checkpoint inhibitors, IL-15 agonists, viral gene therapies and therapeutic cancer vaccines.
This review paper aims to provide an overview of recent developments in the field of allergic and non-allergic rhinitis, as well as allergen immunotherapy.
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction...
The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination (FAD) recommending Blincyto (blinatumomab) from...
Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades.
Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for Blincyto (blinatumomab) to include...
Amgen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include overall survival...